Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors
- PMID: 21192146
- DOI: 10.1097/JCP.0b013e31820469ea
Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors
Abstract
Recent advances clarifying the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors that have not been considered in depth lately are discussed. These new data elucidate aspects of enzyme inhibition and pharmacokinetic interactions involving amine oxidases, cytochrome P450 enzymes, aminotransferases (transaminases), and decarboxylases (carboxy-lyases) and the effects of tyramine. Phenelzine and tranylcypromine remain widely available, and many publications have data relevant to this review. Their effect on CYP 450 enzymes is less than many newer drugs. Tranylcypromine only inhibits CYP 450 2A6 (selectively and potently). Phenelzine has no reported interactions, but, like isoniazid, weakly and irreversibly inhibits CYP 450 2C19 and 3A4 in vitro. It might possibly be implicated in interactions (as isoniazid is). Phenelzine has some clinically relevant inhibitory effects on amine oxidases, aminotransferases, and decarboxylases, and it lowers pyridoxal phosphate levels. It commonly causes pyridoxal deficiency, weight gain, sedation, and sexual dysfunction, but only rarely causes hepatic damage and failure, or neurotoxicity. The adverse effects and difficulties with monoamine oxidase inhibitors are less than previously believed or estimated, including a lower risk of hypertension, because the tyramine content in foods is now lower. Potent norepinephrine reuptake inhibitors have a strong protective effect against tyramine-induced hypertension. The newly discovered trace amine-associated receptors probably mediate the pressor response. The therapeutic potential of tranylcypromine and L-dopa in depression and Parkinson disease is worthy of reassessment. Monoamine oxidase inhibitors are not used to an extent proportionate with their benefits; medical texts and doctors' knowledge require a major update to reflect the evidence of recent advances.
Similar articles
-
An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid.Br J Clin Pharmacol. 2006 May;61(5):570-84. doi: 10.1111/j.1365-2125.2006.02627.x. Br J Clin Pharmacol. 2006. PMID: 16669850 Free PMC article.
-
Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6.Cell Mol Neurobiol. 2004 Feb;24(1):63-76. doi: 10.1023/b:cemn.0000012725.31108.4a. Cell Mol Neurobiol. 2004. PMID: 15049511
-
Tranylcypromine in mind (Part I): Review of pharmacology.Eur Neuropsychopharmacol. 2017 Aug;27(8):697-713. doi: 10.1016/j.euroneuro.2017.05.007. Epub 2017 Jun 24. Eur Neuropsychopharmacol. 2017. PMID: 28655495 Review.
-
Effect of inhibitors of monoamine oxidase on various enzymes and on the storage of monoamines.Ann N Y Acad Sci. 1963 Jul 8;107:1147-51. doi: 10.1111/j.1749-6632.1963.tb13357.x. Ann N Y Acad Sci. 1963. PMID: 13947443 No abstract available.
-
Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review.J Psychiatry Neurosci. 1992 Nov;17(5):206-14. J Psychiatry Neurosci. 1992. PMID: 1362653 Free PMC article. Review.
Cited by
-
Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review.Front Pharmacol. 2023 Sep 19;14:1267294. doi: 10.3389/fphar.2023.1267294. eCollection 2023. Front Pharmacol. 2023. PMID: 37795032 Free PMC article. Review.
-
On the Origins of MAOI Misconceptions: Reaffirming their Role in Melancholic Depression.Psychopharmacol Bull. 2023 Aug 11;53(3):35-54. Psychopharmacol Bull. 2023. PMID: 37601082 Review.
-
Phenelzine-based probes reveal Secernin-3 is involved in thermal nociception.Mol Cell Neurosci. 2023 Jun;125:103842. doi: 10.1016/j.mcn.2023.103842. Epub 2023 Mar 15. Mol Cell Neurosci. 2023. PMID: 36924917 Free PMC article.
-
The Prescriber's Guide to the MAOI Diet-Thinking Through Tyramine Troubles.Psychopharmacol Bull. 2022 May 31;52(2):73-116. Psychopharmacol Bull. 2022. PMID: 35721816 Free PMC article. Review.
-
Monoamine Oxidase Inhibition by Plant-Derived β-Carbolines; Implications for the Psychopharmacology of Tobacco and Ayahuasca.Front Pharmacol. 2022 May 2;13:886408. doi: 10.3389/fphar.2022.886408. eCollection 2022. Front Pharmacol. 2022. PMID: 35600851 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical